Enhancing Survival Through Innovative Immune Modulation
[/split_line_heading]
We are a late-stage clinical company developing microbiome therapies to modulate the immune system and improve cancer survival.
[divider line_type=”No Line” custom_height=”20″][nectar_btn size=”jumbo” button_style=”see-through-2″ color_override=”#ffffff” hover_color_override=”#ffffff” hover_text_color_override=”#000000″ icon_family=”none” text=”See News” url=”#press” margin_left=”0″ margin_right=”36″]We are a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.
As a pioneer, MaaT Pharma has reached a major milestone in its development in January 2025, with positive topline results from its Phase 3 clinical trial evaluating its microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.